| Angela Alves Cabral, MD | |
|
100 Walter Hannon Parkway, Quincy, MA 02169 | |
| (617) 615-4100 | |
| Not Available |
| Full Name | Angela Alves Cabral |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 100 Walter Hannon Parkway, Quincy, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518377696 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 259825 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Hospital - Milton | Milton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Care Of Boston Management Corporation | 6800787714 | 234 |
News Archive
A multidisciplinary national research team led by University of Utah Health scientists has launched a comprehensive review and analysis of data collected about COVID-19 in hopes of improving the nation's ability to predict, detect, and respond to future pandemics.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.
SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.
Many parents worry about the potential influence the media may have on their children's self-esteem and body image. Stories about young women having excessive plastic surgery are enough to keep any parent up at night.
› Verified 7 days ago
| Entity Name | Medical Care Of Boston Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437196359 PECOS PAC ID: 6800787714 Enrollment ID: O20040322000778 |
News Archive
A multidisciplinary national research team led by University of Utah Health scientists has launched a comprehensive review and analysis of data collected about COVID-19 in hopes of improving the nation's ability to predict, detect, and respond to future pandemics.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.
SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.
Many parents worry about the potential influence the media may have on their children's self-esteem and body image. Stories about young women having excessive plastic surgery are enough to keep any parent up at night.
› Verified 7 days ago
| Entity Name | Community Health Connections, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477580827 PECOS PAC ID: 8729074992 Enrollment ID: O20040422001136 |
News Archive
A multidisciplinary national research team led by University of Utah Health scientists has launched a comprehensive review and analysis of data collected about COVID-19 in hopes of improving the nation's ability to predict, detect, and respond to future pandemics.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.
SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.
Many parents worry about the potential influence the media may have on their children's self-esteem and body image. Stories about young women having excessive plastic surgery are enough to keep any parent up at night.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela Alves Cabral, MD 100 Walter Hannon Parkway, Quincy, MA 02169-1919 Ph: (617) 615-4100 | Angela Alves Cabral, MD 100 Walter Hannon Parkway, Quincy, MA 02169 Ph: (617) 615-4100 |
News Archive
A multidisciplinary national research team led by University of Utah Health scientists has launched a comprehensive review and analysis of data collected about COVID-19 in hopes of improving the nation's ability to predict, detect, and respond to future pandemics.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
PharmaMar has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be conducted in 10 European clinical centres and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.
SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.
Many parents worry about the potential influence the media may have on their children's self-esteem and body image. Stories about young women having excessive plastic surgery are enough to keep any parent up at night.
› Verified 7 days ago
Roger Lu, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1690 Crown Colony Dr, Quincy, MA 02169 Phone: 857-403-4600 | |
John Loughnane, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 205 Parkingway, Quincy, MA 02169 Phone: 617-820-5968 Fax: 833-471-5603 | |
Sergio Ramoa, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 Hancock St, Quincy, MA 02169 Phone: 617-774-0840 Fax: 617-774-0882 | |
Dr. Rita P Wadhwani, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 114 Whitwell St, 2 Nd Floor B Wing, Quincy, MA 02169 Phone: 617-376-3000 Fax: 617-774-1906 | |
Obli Chetty Maragatha Mani, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 Hancock St, Internal Medicine, Quincy, MA 02169 Phone: 617-774-0840 Fax: 617-774-0882 | |
Jee Chung Lin, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1250 Hancock St, Quincy, MA 02169 Phone: 617-774-0840 | |
Dr. Natalie Catherine Morson, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 110 W Squantum St, Quincy, MA 02171 Phone: 617-376-3000 |